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THROMBOXANE GENERATION BY HUMAN MONOCYTES
ENHANCES PLATELET FUNCTION
By DARIO C. ALTIERI AND PIER MANNUCCIO MANNUCCI
From the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and Institute ofInternal
Medicine, University ofMilano and Maggiore Hospital, 20122 Milano, Italy
Human blood monocytes interact with some plasma proteins involved in
hemostasis (1, 2) and promote the activation of the coagulation pathway. This
monocyte procoagulant activity (PCA), culminating in local deposition of fibrin,
is essential for cell-mediated immunity (3). To characterize better the pathways
common to immunity and hemostasis, we investigated whether monocytes, in
addition to the clot-promoting activity, also influence the function of platelets.
We have found that a specific receptor-ligand interaction mediated by a typical
hemostatic protein (fibrinogen) triggers the activation by monocytes of the
cyclooxygenase pathway. Furthermore, the monocyte thromboxane (Tx) pro-
duced under these conditions has a dramatic proaggregating effect on platelets.
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Preparation of Cells.
￿
Blood obtained after informed consent from drug-free healthy
donors was anticoagulated with acid/citrate dextrose solution. Platelets and platelet-free
suspensionsofhuman monocyteswere prepared and characterizedaspreviously described
in detail (2).
Measurement ofPlatelet Function.
￿
Platelet aggregation studies were carried out at 37'C
with continuous agitation at 1,000 rpm in an ELVI aggregometer (Milan, Italy). Aliquots
(0.25 ml) of washed platelet suspensions (4 X 108/ml) were stimulated with ADP (1-10
,M; Sigma Chemical Co., St. Louis, MO) in the presence of purified fibrinogen (4.4 X
10-7 M). Each curve was monitored for 3 min. In some experiments, 10 mM EDTA
(Sigma Chemical Co.) or 10 Aig/ml of 10E5 mAb to the glycoprotein IIb/IIIa complex
(GP IIb/IIIa), kindly supplied by Dr. B. S. Coller, State University of New York, Stony
Brook NY, were preincubated for 3 min with the platelet suspension at 37 °C, without
agitation, before the addition of the agonists. '25I-Fibrinogen binding to ADP (10 UM)-
stimulated platelets was carried out basically as described by Kornecki et al. (4). "51-
Fibronogen binding to platelets was first studied in time-course experiments with a fixed
concentration of labeled fibringen (0.2 X 10-" M). For dose-response studies, increasing
concentrations (0.02-8 .8 X 10-7 M) of 1251-fibrinogen were incubated at equilibrium with
ADP-stimulated platelets.
The effect of autologous monocytes on platelet function was investigated as follows.
Mixtures ofwashed platelets (4 X 108/ml) and various concentrations of monocytes (0.5-
2 X 10'/ml) were prepared in the same final volume as control suspensions of platelets
without monocytes. Platelet aggregation and 125I-fibrinogen binding to ADP (1-10 AM)-
stimulated platelet/monocyte mixtures were carried out as described above for suspensions
of platelets only .
Tx Production.
￿
TxB2 (stable metabolite of TxA2) formed during aggregation or 1251_
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FIGURE 1 .
￿
Effects of autologous added monocytes (M¢) (5 X 106/ml) on the aggregation of
washed platelets (Welts) (4 X 10'/ml) stimulated with 10 ,UM (A) or 1 AM (B) ADP (arrow) in
the presence of 4.4 X 10' M fibrinogen. No increase in transmittance was seen when
monocytes (0.25 ml; 2 X 10'/ml) without platelets were challenged with ADP (1-100 AM) and
fibrinogen (4.4 X 10' M), thus excluding that these cells participate in the formation of the
aggregates. Finally, the ADP-induced aggregation of platelets, with or without monocytes, was
equally blocked by 10 mM EDTA or by 10E5 mAb, confirming that the presence of monocytes
potentiated the physiological mechanisms of platelet aggregation. LTU, Light transmission
unit.
fibrinogen binding in platelet suspensions or in mixtures of platelets plus monocytes was
measured by RIA (5). Specific antibody against TxB2 was kindly supplied by Dr. J. B.
Smith, Cardeza Foundation, Philadelphia, PA . In some experiments, monocytes (5 X 106/
ml) were preincubated with 10 uM of the cyclooxygenase inhibitor indomethacin (Sigma
Chemical Co.) for 45 min at room temperature. Platelet aggregation, 1251-fibrinogen
binding and TxB2 measurement in mixtures of platelets plus indomethacin-treated mon-
ocytes were carried out as described above.
Cellular Source and Requirements for TxB2 Production.
￿
Additional experiments were
performed to identify the origin of TxB2 formed in platelet/monocyte mixtures during
platelet aggregation and 1251-fibrinogen binding. Aliquots of monocyte suspensions (5 X
10'/ml) were incubated without platelets but with 10 AM ADP and I mM CaC12 for 5
min at room temperature in the presence of increasing concentrations of fibrinogen
(0.17-7.3 X 10-' M). Controls were platelets (4 X 10'/ml) in the absence of monocytes
incubated under the same experimental conditions. At the end of the incubation, cell
suspensions were centrifuged at 12,000 g for 2 min at room temperature and the
supernatant was assayed for TxB2. TxB2 was measured in suspensions of monocytes (5 X
10'/ml) without platelets incubated for 5 min at room temperature in the presence of I
mM CaCl2, either with l0 uM ADP only or with 7 .3 X 10' M fibrinogen only. Finally,
aliquots of monocyte suspensions (5 X 10'/ml) were preincubated with 10 mM EDTA or
20 mg/ml of 10E5 mAb for 3 min at room temperature before the addition of ADP and
fibrinogen. Monocyte TxB2 formed under these conditions was measured as described
above.
Effects ofAutologous Monocytes on Platelet Function.
￿
Fig. 1 compares the aggre-
gating response of platelets or platelet/monocyte mixtures with subthreshold
concentrations of ADP. Washed platelets stimulated with 10 AM ADP (Fig. 1 A)
had a single reversible wave of aggregation, or only a slight transient increase in
transmittance when lower concentrations of ADP (I AM) were used (B). In
contrast, monocytes mixed with platelets induced a prompt irreversible wave of
aggregation (A) or a biphasic curve with a typical release reaction (Fig. 1 B).
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data complementary to those of the aggregation studies. In fact, in time-course
experiments, the amount of 125I-fibrinogen bound to platelets was four to five
times greater in the presence of monocytes than in suspensions ofplatelets only
(Fig. 2A). Dose-response studies showed that for each concentration of 1211_
fibrinogen added, mixtures ofplatelets plus monocytesbound three to four times
more labeled protein than platelets only (Fig. 2B).
Mechanisms ofMonocyte Enhancement ofPlatelet Function.
￿
We asked ourselves
whether a soluble factor released by monocytes under these conditions was
responsible for the potentiation of platelet function. We focused our attention
on Tx because it is a major product of the monocyte cyclooxygenase pathway
(6). and its proaggregating effect on platelets is well known (7). RIA measure-
ments revealed that the enhancement of platelet aggregation seen in platelet/
monocyte mixtures was associated with the formation of 65 ± 10 pmol/ml of
TxB2 (means ± SE, four experiments), while only 5.3 ± 2 pmol/ml ofTxB2 were
formed during the aggregation of platelets alone (four experiments). Table I
shows that the increased binding of fibrinogen to platelets in platelet/monocyte
mixtures was also associated with progressively more synthesis of TxB2. In
contrast, TxB2 formed in suspensions of platelets only was insignificant for each
concentration of fibrinogen tested (Table I). Furthermore, when monocytes
were preincubated with 10 gM indomethacin and mixed with platelets, the
enhancement ofplatelet aggregation and í25I-fibrinogen binding was completely
suppressed. Control experiments showed that under these conditions the synthe-
sis of TxB2 in mixtures of platelets plus indomethacin-treated monocytes was
abolished (Table 1). The requirements for the synthesis of TxB2 by monocytes
were further investigated. Monocytes without platelets but in the presence of
CaC12, ADP, and fibrinogen generated the same amounts ofTxB2 as in mixtures
ofplatelets plus monocytes under the same experimental conditions (not shown).
This excludes a collaborative participation of platelets in inducing TxB2 forma-
tion by monocytes. Furthermore, effective synthesis ofTxB2 occurred only after
monocyte incubation with both ADP and fibrinogen (Table II). Similarly, after
cell treatment with EDTA or 10E5 mAb the monocyte generation of TxB2 was
suppressed to basal values (Table II).
Discussion
In this study, we showed that human monocytes, in addition to PCA, greatly
enhance the aggregation of platelets. Monocyte potentiation of platelet aggre-
gation is rapid and is due to an increased binding of fibrinogen to platelets. We
investigated the possibility that the monocyte-induced enhancement of platelet
aggregation followed the pathways generally involved in the modulation of
immune reactions. In fact, the monocytes regulate inflammation through the
release of soluble factors, particularly arachidonic acid metabolites. Prostaglan-
dins of the E series modulate the tumoricidal functions (8), leukotrienes are
specific inflammatory mediators of allergic reactions (9) and Tx is involved in
natural cytotoxic activity (10) and has proaggregating properties (7). Therefore,
the role of monocyte Tx in enhancing platelet aggregation was investigated.
While virtually no TxB2 was produced during ADP activation ofplatelets only,
the enhancement ofplatelet function in mixtures of platelets plus monocytes was1818
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FIGURE 2.
￿
Time-course (A) and dose-response curve (B) of ' 251-fibrinogen-specific binding
to ADP (10 uM)-stimulated platelets (4 X 108/ml) in the presence (filled square) or in the
absenceof (filled circle) of monocytes (5 X 108/ml). Underthese conditions both platelets and
monocytes bound 1251-fibrinoen. However, control experiments not shown in the figure
revealed that theamount of
12fI-fibrinogen boundby 5 X 108 monocytes/ml was insignificant
as compared with platelet-bound fibrinogen: 0.007 ug/108 monocytes (1 .4 X 10- M
1211_
fibrinogen added); 0.013 ti/108 monocytes (3 X 10-7 M 1251-fibrinogen added); 0.024 jug/106
monocytes (7.3 X 10-7 M
121I-fibrinogen added). Therefore, 1251-fibrinogen bound in platelet-
monocyte mixtures was not significantly overestimated because of the amount of specific
monocyte-bound fibrinogen. Specific binding data were analyzed by the method of Scatchard.
Twoclasses of receptors were found. The values for binding constants (Kd) were similar with
or without monocytes(platelets/platelet-monocyte mixtures: low-affinity Ka = 8.2/2.4 X 10'
M; high-affinity Kd = 1 .92/2.8 X 10-8 M). In contrast, a sevenfold increase in the number of
high-affinity fibrinogen receptors was found in the platelet/monocyte mixture (n = 7,620)
over that in platelets only (n = 1,160). Smaller differences were seen in the number of low-
affinity receptors (platelets/platelet-monocyte mixtures: 30,120/44,800). Each point is the
mean of three different experiments.
associated with generation of large amounts of TxB2. Similarly, the synthesis of
TxB2 and the enhancement of platelet function were completely suppressed after
preincubation of monocytes with indomethacin. These findings confirmed thatALTIERI AND MANNUCCI
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TABLE I
'151-Fibrinogen (` 251-FG)-specific Binding and TxB2 Production in Suspensions ofADP
(10 AM)-stimulated platelets (Welts), mixtures ofplateletsplus monocytes(Welts + M46),
mixtures ofplatelets plus indomethacin-treated monocytes (Welts + indo-M(k)
Welts
￿
Welts + MO
￿
Welts + indomethacin-Mo
1251-Fibrinogen binding and TxB2 measurement were performed as described in Materials and Methods. Results
are means ± SE (four experiments).
TABLE II
Requirementsfor the Synthesis of TxB2 by Monocytes
Experimental procedures and TxB2 measurement as described in Materials and Methods.
Results are means ± SE.
* 10E5, mAb blocking the receptor for fibrinogen on monocytes.
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the TxB2 measured in platelet/monocyte mixtures was of monocyte origin and
directly responsible for the effect on platelets.
Previous studies (11) indicate that the common denominator for the monocyte
prostaglandin production is a "membrane perturbation" occurring after the
binding ofa ligand to its specific cell surface receptor. We recently showed (2)
that monocytes possess an ADP-inducible receptor for fibrinogen and that the
interaction of fibrinogen with monocytes induces rapid expression of PCA by
these cells. We now show that only after the ADP-induced interaction of fibrin-
ogen with monocytes is there synthesis ofTxB2 by these cells. Without a stimulus
(ADP) or the ligand (fibrinogen), or when Ca2+ ions have been removed (cell
preincubation with EDTA), fibrinogen does not interact with monocytes, and
the synthesis of TxB2 is abolished. Similarly, when the receptor for fibrinogen
on monocytes is blocked by 10E5 mAb there was no synthesis of TxB2. There-
fore, fibrinogen itself might function as a soluble membrane-perturbing agent to
induce, like the classical inflammatory stimuli, the synthesis of TxB2 by mono-
cytes. The biological relevance of this phenomenon is reflected in the dramatic
enhancement of platelet response to a stimulus such as ADP, which is relatively
ubiquitous in vivo.
In conclusion, the data presented here further emphasize the role of human
monocytes as regulatory cells of several biologic systems. Furthermore, plasma
'451-FG added
(X 10-' M)
1251-FG bound
(molecules/plate-
let)
(pTxB2
mol/ml)
'451-FG bound
(molecules/plate-
let)
(pTxB2
mol/ml)
"5I-FG bound
(molecules/plate-
let)
TxB
(pmol/ml)
0.1 586 ± 180 0.5 2,610 ± 1,280 21 ± 8 300 ± 78 0.5
0.3 1,192 ± 310 1 .0 5,675 ± 2,641 27 t 10 ND ND
0.7 2,176 t 500 0.9 7,383 t 4,200 32 t 14 1,424 ± 12 1 .0
1.4 4,129 ± 900 0.2 12,814 t 6,530 44 t 4 2,715 ± 25 0.5
3.0 6,390 ± 2,050 0.2 19,600 ± 9,000 50 ± 15 4,552 ± 311 1 .5
7.3 12,210 ± 4,677 0.5 30,500 ± 8,000 74 ± 17 ND ND
Cell suspension Number of
experiments TxB2 (pmol/ml)
Monocytes + RPMI 1640 4 14 f 1 .4
Monocytes + ADP + fibrinogen 4 115 ± 12.5
Monocytes + ADP 6 20 t 8.06
Monocytes + fibrinogen 6 14 t 9.08
EDTA-treated monocytes 6 16.5 f 3.9
10E5*-treated monocytes 6 18.5 ± 7.11820
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fibrinogen appears to have the same mechanisms as inflammatory stimuli for
inducing monocyte prostaglandin production.
Summary
Human monocytes potentiate the ADP-stimulated aggregation of autologous
platelets through a fourfold increased binding of 1251-fibrinogen to the platelet
surface. The enhancement of platelet function is rapid, relatively transient and
is due to thromboxane (Tx) synthesized by monocytes under these conditions.
Tx generation by monocytes is triggered by the interaction between fibrinogen
and the specific monocyte membrane receptor. These data suggest that the
monocyte enhancement of platelet function combined with the clot-promoting
activity of these cells might unbalance normal hemostasis.
Receivedforpublication 22 July 1986 and in revisedform 3September 1986.
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